This CME/CNE activity will provide a comprehensive update of best practices for treating and managing patients with multiple sclerosis (MS), including data presented at American Academy of Neurology (AAN) 2019 Annual Meeting. The expert faculty will review strategies for early detection and intervention in MS, referencing the McDonald Criteria. Recent clinical trial data, including extension data of emerging and emerged therapeutic agents will be analyzed. The clinical relevance of neurofilament light chain (NfL) in modern day multiple sclerosis care will be debated in an interactive panel format. The faculty will relay optimal strategies for providing personalized care. Upon completion of this education, learners will be better equipped to confidently treat and manage patients with multiple sclerosis.
Neurologists, internists, nurse practitioners, nurses, physician assistants and other healthcare providers involved in the management of patients with multiple sclerosis
- Understand the role of immune-inflammation in relapsing multiple sclerosis, as well as diagnostic criteria for the disease
- Analyze clinical trial data of novel S1P therapeutics to treat relapsing multiple sclerosis, including data presented at AAN 2019
- Collaborate with the interprofessional team to develop individualized treatment plans to decrease disease activity and improve the overall quality of life of patients with relapsing multiple sclerosis
Fred D. Lublin, MD (Course Chair)
Saunders Family Professor of Neurology
Director, Corinne Goldsmith Dickinson Center for MS
Icahn School of Medicine at Mount Sinai
New York, New York
Disclosures of Conflict of Interest
It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CNE activity:
|Faculty||Relationship Identified With:|
|Fred D. Lublin, MD||Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals; Apitope; Atara Biotherapeutics; Biogen; Brainstorm Cell Therapeutics; Celgene Corporation; EMD Serono; Forward Pharma; Genentech, Inc.; Genzyme Corporation; GW Pharmaceuticals; Innate Immunotherapeutics; Jazz Pharmaceuticals; MedDay Pharmaceuticals; Mapi Pharma; MedImmune; Novartis Pharmaceuticals Corporation; Orion Biotechnology; Polpharma; Receptos, Inc.; Regeneron; Roche; Sanofi; Teva Pharmaceuticals; TG TherapeuticsSpeaker’s Bureau: Sanofi|
|Stephen Krieger, MD||Consultant/Advisor: Biogen; EMD Serono; Genentech, Inc.; Genzyme Corporation; Mallinckrodt; MedDay Pharmaceuticals; Novartis Pharmaceuticals Corporation; Teva Pharmaceuticals; TG TherapeuticsSpeaker’s Bureau: Biogen; Novartis Pharmaceuticals Corporation|
|Clyde Markowitz, MD||Consultant/Advisor: Actelion Pharmaceuticals; Alexion; Biogen; Bayer AG; Celgene Corporation; EMD Serono; Genentech, Inc.; Genzyme Corporation; Novartis Pharmaceuticals Corporation; Roche; Sanofi; Teva Pharmaceuticals|
Planners, Managers and Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statement
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AcademicCME designates this enduring material for a maximum of 1.0 CNE contact hour (1.0 CNE pharmacotherapeutic contact hour). AcademicCME’s ANCC provider number is P0491.
This activity has been supported by an independent educational grant from Celgene Corporation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Celgene Corporation do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CPE credit will be posted to the learner’s CPE Monitor profile within 60 days of completion.
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CME/CNE inquiries or special needs, please contact [email protected].